Cignas 2026 commercial PA criteria for Wegovy require five elements: BMI of 30 or higher, or BMI 27 to 29.9 with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, OSA, CVD), documentation of a structured weight management program for at least 6 months in the past 24 months, prescriber attestation that lifestyle changes alone have been inadequate, age 18 or older, and concurrent reduced-calorie diet and physical activity
history taking, clinical examination, validated IIEF-5 questionnaire, estimation of serum l-carnitine by calorimetric method and serum 25(OH)D by ELISA method
Three different strengths are available across these vials
4.1 Limitations and implications for practice This meta-analysis has several limitations that should be considered when interpreting the findings